PHILADELPHIA—At the second Plenary Session of ACR Convergence on Sunday, Nov. 13, speakers shared compelling efficacy and safety results from two phase 2 trials: remibrutinib for Sjögren’s syndrome and deucravacitinib for moderate to severe systemic lupus erythematosus. Remibrutinib in Phase 2 Sjögren’s Syndrome Trial Thomas Dörner, MD, a professor of rheumatology and clinical immunology for…
Sindhu Johnson, MD, PhD, FRCPC, has co-chaired the classification and response criteria subcommittee and brings extensive experience in classification and guideline development to her new role.
A recent study explored medical concerns for patients who have lupus markers, but fall short of meeting enough criteria for official disease classification. Investigators at the Oklahoma Medical Research Foundation conducted a large study to explore current treatments of patients with incomplete lupus erythematous (ILE) and to compare antibody characteristics to healthy people and patients…
Patient histories, clinician reports of condition also called Köhlmeier-Degos disease underscore need for integrated, multidisciplinary care
A stretch-limo ride with academic rheumatologists leads to reflection
Systemic lupus erythematosus, often called SLE or lupus, is a chronic inflammatory disease that can affect the skin, joints, kidneys, lungs, nervous system, and other organs of the body. It is sometimes labeled the “great imitator” because its wide variety of symptoms can often be confused with other disorders. Usually, patients with SLE experience skin rashes and arthritis as well as fatigue and fever, and the disease can be fatal. However, improvements in therapy have significantly increased these patients’ quality of life and their life expectancy.
How to minimize the risks of pregnancy for women with SLE
A Day in the Life of Cynthia Aranow, MD